# Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

> **NCT00261950** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 110 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Sensipar (Cinacalcet HCl)

## Key facts

- **NCT ID:** NCT00261950
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261950, "Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00261950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*